|Bid||217.57 x 100|
|Ask||259.99 x 400|
|Day's Range||258.76 - 264.48|
|52 Week Range||244.28 - 370.57|
|PE Ratio (TTM)||21.75|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Wall Street analysts expect an ~3.0% increase in Eli Lilly & Co.’s (LLY) 1Q18 revenues to $5.5 billion. Eli Lilly’s products are sold in more than 120 countries, and its international sales comprise ~45.0% of its total revenues. As a result, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenues during 1Q18.
Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.
Below is a list of notable corporate events for the week beginning April 23. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on AMD Monday ...
Ionis rocketed in early trading Friday after announcing a $1 billion deal with Biogen to develop treatments for neurological diseases like dementia in a follow-up to Spinraza's success.
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is almost flat for the week after adding about 5 percent in the week ended April 13. Will the following catalytic events lead to a resumption ...
Biogen's shares, however, fell about 2 percent as investors were looking for a larger deal, especially after rival Novartis AG last week said it would buy AveXis Inc for $8.7 billion to gain access to its gene therapy for spinal muscular atrophy. "Given the fact that just happened and ...here they are a week later not buying that company and doing a $1 billion pre-clinical deal, I think the Street remains very nervous and uncertain," Jefferies analyst Michael Yee told Reuters.
On the Q1 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
The companies previously collaborated to develop a treatment for a rare infant disorder that won FDA approval in December 2016. They will pursue similar drugs under the deal announced Friday.
Ionis Pharmaceuticals Inc. is on track to shake off an 8.9 percent year-to-date decline after its pharma partner, Biogen Inc., became the second-biggest holder as part of a $1 billion deal.
Shares of Ionis Pharmaceuticals Inc. soared 8.4% in premarket trade Friday, after Biogen Inc. said it would pay the company $1 billion as part of a new 10-year collaboration agreement to develop drug candidates ...
Drugmaker Biogen Inc said on Friday it would pay Ionis Pharmaceuticals Inc $1 billion in cash as part of a new ten-year agreement to develop medicines for a broad range of neurological diseases including ...
Biogen will pay Ionis Pharmaceuticals $1 billion to expand the companies' collaboration around brain drugs for another ten years. Like Spinraza, future drugs in the collaboration will use antisense. Instead of working on proteins, as most medicines do, antisense drugs interfere with RNA, which carries genetic messages from inside the cell nucleus to the cell's protein-making machinary.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, and other biotechnology assets have recently been slumping, but some analysts believe big biotechnology ...
Voyager Therapeutics (VYGR) spent $61.3 million on operating activities in 2017 compared to $42.4 million in 2016. In comparison, it generated $47.3 million from investing activities in 2016. The company’s positive investing cash flow in 2016 was attributable to proceeds from the maturities of marketable securities of $165.1 million, and it was partially offset by securities purchases of $112.4 million.
Biogen (BIIB) is a global biopharmaceutical company with a focus on core areas of multiple sclerosis (or MS), neuroimmunology, Alzheimer’s disease, dementia, spinal muscular atrophy (or SMA), and amyotrophic lateral sclerosis (or ALS). Approved by the FDA for the treatment of SMA in pediatric and adult patients in December 2016, Spinraza is one of Biogen’s key products.
Dr. Stanley Crooke Ionis President discusses why he is optimistic about the deal between Biogen and Ionis to fight brain disease.
Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.